logo-loader
viewAzurRx BioPharma Inc

Full interview: AzurRx BioPharma aiming to cure gut diseases with its yeast-based enzyme therapies

AzurRx BioPharma (NASDAQ:AZRX) CEO Thijs Spoor tells Proactive the New York-based biopharma that its yeast technology - which comes from blue cheeses - can be used to produce large amounts of enzymes to treat patients with gut disorders.

Spoor says the current standard of care to treat gut disorders like cystic fibrosis requires patients to take 40 pills per day made of pig pancreas; AzurRx is aiming to drastically cut this down with its therapy.

Quick facts: AzurRx BioPharma Inc

Price: 1.01 USD

NASDAQ:AZRX
Market: NASDAQ
Market Cap: $27.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks finish week in the red; Canaccord initiates...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was down 2.6% higher at 117.4 points. Elsewhere, the OTCQX Cannabis index fell 1.8% to 480.1 points. Buds today were Pharmacielo Ltd (CVE:PCLO), The Valens Company (CVE:VLNS) (OTCMKTS:VLNCF)....

2 days, 18 hours ago

2 min read